Georg Stussi

13PUBLICATIONS
65CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Medical molecular engineering of nucleic acids and proteinsMolecular targetsHaematological tumoursRegenerative medicine (incl. stem cells)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Jul 14, 2025
IL-16 production is a mechanism of resistance to BTK inhibitors and R-CHOP in lymphomas.

Alberto J Arribas, Francesca Guidetti, Eleonora Cannas

|Oct 07, 2024
PI3Kδ activation, IL-6 overexpression, and CD37 loss cause resistance to naratuximab emtansine in lymphomas.

Alberto J Arribas, Sara Napoli, Eugenio Gaudio

|Dec 05, 2023
ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid Neoplasms.

Alberto J Arribas, Sara Napoli, Luciano Cascione

|Nov 28, 2023
PI3Kδ activation, IL6 over-expression, and CD37 loss cause resistance to the targeting of CD37-positive lymphomas with the antibody-drug conjugate naratuximab emtansine.

Alberto J Arribas, Eugenio Gaudio, Sara Napoli

|Jun 19, 2023
Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabine.

Jacobien R Hilberink, Isabelle A van Zeventer, Dana A Chitu

|Jan 30, 2023
ERBB4-mediated signaling is a mediator of resistance to BTK and PI3K inhibitors in B cell lymphoid neoplasms.

Alberto J Arribas, Sara Napoli, Luciano Cascione

Pageof 3

Frequent Collaborators

6 joint publications

Francesco Bertoni

5 joint publications

Chiara Tarantelli

5 joint publications

Alberto J Arribas

5 joint publications

Sara Napoli